Free Trial

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie logo
$175.58 +4.06 (+2.37%)
(As of 12/20/2024 05:45 PM ET)

AbbVie - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
5
Buy
19

Based on 24 Wall Street analysts who have issued ratings for AbbVie in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 5 have given a hold rating, 17 have given a buy rating, and 2 have given a strong buy rating for ABBV.

Consensus Price Target

$205.70
17.15% Upside
According to the 24 analysts' twelve-month price targets for AbbVie, the average price target is $205.70. The highest price target for ABBV is $225.00, while the lowest price target for ABBV is $180.00. The average price target represents a forecasted upside of 17.15% from the current price of $175.58.
Get the Latest News and Ratings for ABBV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AbbVie and its competitors.

Sign Up

ABBV Analyst Ratings Over Time

TypeCurrent Forecast
12/24/23 to 12/23/24
1 Month Ago
11/24/23 to 11/23/24
3 Months Ago
9/25/23 to 9/24/24
1 Year Ago
12/24/22 to 12/24/23
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
17 Buy rating(s)
18 Buy rating(s)
12 Buy rating(s)
8 Buy rating(s)
Hold
5 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
9 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$205.70$203.50$191.64$167.59
Forecasted Upside17.15% Upside15.00% Upside-1.01% Downside8.16% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold

ABBV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AbbVie Stock vs. The Competition

TypeAbbVieMedical CompaniesS&P 500
Consensus Rating Score
2.88
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside17.15% Upside25,827.31% Upside14.53% Upside
News Sentiment Rating
Positive News

See Recent ABBV News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/17/2024Piper Sandler Companies
5 of 5 stars
 Reiterated RatingOverweight ➝ Overweight$220.00+25.13%
12/10/2024Bank of America
3 of 5 stars
 Reiterated RatingNeutral$191.00+8.14%
12/5/2024Daiwa America
0 of 5 stars
N. Nakagiri
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
12/5/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$180.00+1.95%
11/22/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
11/22/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$206.00+19.64%
11/19/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$195.00+17.80%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hammond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$205.00+20.85%
11/13/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$210.00 ➝ $200.00+16.74%
11/12/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Verdult
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$226.00 ➝ $215.00+24.27%
11/12/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$228.00 ➝ $208.00+18.74%
11/12/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$231.00 ➝ $224.00+28.41%
11/6/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$212.00 ➝ $221.00+9.36%
11/4/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Toung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
10/31/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$195.00 ➝ $200.00-1.87%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Breen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$203.00+6.58%
10/10/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$210.00 ➝ $215.00+10.49%
10/7/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$200.00 ➝ $212.00+9.75%
10/7/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$195.00 ➝ $225.00+16.22%
8/30/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Phipps
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/5/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00+8.40%
6/5/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$185.00+14.08%
2/5/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$181.00 ➝ $189.00+12.05%
12/11/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$173.00+15.89%
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$150.00+5.60%
7/12/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$170.00 ➝ $160.00+18.02%
2/10/2023Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$157.00 ➝ $154.00+1.83%
2/10/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform$135.00 ➝ $153.00+2.89%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 08:54 AM ET.


Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, December 15, 2024. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

AbbVie
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in AbbVie:

  • AbbVie has a strong market capitalization of approximately $308.14 billion, indicating a robust financial position and stability in the market.
  • The company reported earnings of $3.00 per share, exceeding analyst expectations, which reflects strong operational performance and profitability.
  • AbbVie has a diverse portfolio of products, including recent innovations that contribute to its revenue growth, with quarterly revenue reported at $14.46 billion.
  • Current stock price is around $174.37, which may present a buying opportunity for investors looking for value in a well-established company.
  • Institutional ownership stands at 70.23%, suggesting confidence from large investors in AbbVie’s long-term prospects.

AbbVie
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in AbbVie for these reasons:

  • AbbVie has a high price-to-earnings (P/E) ratio of 60.81, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • The company has a debt-to-equity ratio of 9.64, suggesting a high level of debt relative to equity, which could pose risks in times of economic downturns.
  • Recent price target reductions by analysts, with Citigroup lowering its target from $226.00 to $215.00, may indicate a bearish outlook on the stock's future performance.
  • AbbVie’s stock has shown volatility, with a recent trading range between a twelve-month low of $151.29 and a high of $207.32, which could deter risk-averse investors.
  • Concerns about the sustainability of revenue growth, as the company faces competition and potential patent expirations on key products, could impact future earnings.

ABBV Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $205.70, with a high forecast of $225.00 and a low forecast of $180.00.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 5 hold ratings, 17 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABBV shares.

According to analysts, AbbVie's stock has a predicted upside of 17.15% based on their 12-month stock forecasts.

Over the previous 90 days, AbbVie's stock had 3 upgrades and 2 downgrades by analysts.

Analysts like AbbVie more than other "medical" companies. The consensus rating score for AbbVie is 2.88 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ABBV compares to other companies.


This page (NYSE:ABBV) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners